Advertisement

Wiener klinische Wochenschrift

, Volume 130, Issue 23–24, pp 694–697 | Cite as

Changes and innovations of the 2017 ESC guidelines on dual antiplatelet therapy in coronary artery disease—a review

  • Hannes F. Alber
  • Kurt Huber
review article
  • 63 Downloads

Summary

Duration and compostion of dual antiplatelet therapy has been increasingly changed within the past few years as also indicated in the firmer ESC guidelines. The current manuscript summarizes the most important changes in dual antiplatelet therapy as shown by a recent ESC position paper and offers quick insight into these new developments.

Keywords

Dual antiplatelet therapy Acute coronary syndromes Stable coronary artery disease Atrial fibrillation P2Y12-inhibitors 

Notes

Conflict of interest

H.F. Alber and K. Huber declare that they have no competing interests.

References

  1. 1.
    Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213–60. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the EuropeESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.an Association for Cardio-Thoracic Surgery (EACTS).CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267–315. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).CrossRefPubMedGoogle Scholar
  4. 4.
    Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2014;35(37):2541–619. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).CrossRefPubMedGoogle Scholar
  5. 5.
    Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.CrossRefPubMedGoogle Scholar
  6. 6.
    Holcomb CN, Graham LA, Richman JS, Itani KM, Maddox TM, Hawn MT. The incremental risk of coronary stents on postoperative adverse events: a matched cohort study. Ann Surg. 2016;263:924–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol. 2010;56(3):185–93.CrossRefPubMedGoogle Scholar
  8. 8.
    Gherli R, Mariscalco G, Dalén M, et al. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol. 2016;1:921–8.CrossRefPubMedGoogle Scholar
  9. 9.
    PEGASUS-TIMI 54 Steering Committee and Investigators, Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–800.CrossRefGoogle Scholar
  10. 10.
    DAPT Study Investigators, Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–66.CrossRefGoogle Scholar
  11. 11.
    Ziada KM, Abdel-Latif AK, Charnigo R, et al. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: a systematic review and meta-analysis of randomized trials. Catheter Cardiovasc Interv. 2016;87(4):722–32.CrossRefPubMedGoogle Scholar
  12. 12.
    Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163–70.CrossRefPubMedGoogle Scholar
  13. 13.
    Lee KS, Lee JZ, Hsu CH, et al. Temporal trends in strut-level optical coherence tomography evaluation of coronary stent coverage: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2016;88(7):1083–93.CrossRefPubMedGoogle Scholar
  14. 14.
    Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373(21):2038–47.CrossRefPubMedGoogle Scholar
  15. 15.
    Morice MC, Talwar S, Gaemperli O, et al. Drug-coated versus bare-metal stents for elderly patients: a predefined sub-study of the LEADERS FREE trial. Int J Cardiol. 2017;243(15):110–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Naber CK, Urban P, Ong PJ, et al. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a leaders free ACS sub-study. Eur Heart J. 2017;38(13):961–9.PubMedGoogle Scholar
  17. 17.
    Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025–34.CrossRefPubMedGoogle Scholar
  18. 18.
    Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119–77. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).CrossRefPubMedGoogle Scholar
  19. 19.
    Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.CrossRefPubMedGoogle Scholar
  20. 20.
    Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with Dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–24.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Internal Medicine and CardiologyLandeskrankenhausKlagenfurtAustria
  2. 2.Karl Landsteiner Institute for Interdisciplinary ScienceRehabilitation Centre MünsterMünsterAustria
  3. 3.3rd Department of Medicine, Cardiology and Intensive Care MedicineWilhelminenhospitalViennaAustria
  4. 4.Sigmund Freud UniversityMedical SchoolViennaAustria

Personalised recommendations